Filtros de búsqueda

Lista de obras de Fatima Cardoso

1st International consensus guidelines for advanced breast cancer (ABC 1).

artículo científico

3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

artículo científico publicado en 2002

A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future

artículo científico publicado en 2012

A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments

artículo científico publicado en 2020

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies

artículo científico publicado en 2010

A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer

artículo científico publicado en 2013

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

artículo científico publicado en 2014

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.

artículo científico

A rude awakening from tumour cells

artículo científico publicado en 2018

ASCO 2009: What's New in Breast Cancer Therapy?

artículo científico publicado en 2009

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

artículo científico publicado en 2007

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes

artículo científico publicado en 2013

Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe

scientific article published on 13 December 2020

Adjuvant Chemotherapy of Breast Cancer

artículo científico publicado en 2009

An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®).

artículo científico publicado en 2017

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

artículo científico publicado en 2012

Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

artículo científico publicado en 2017

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

artículo científico publicado en 2020

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

artículo científico publicado en 2009

Autoimmune haemolytic anaemia in a patient treated with capecitabine

artículo científico publicado en 2013

BRCA in breast cancer: ESMO Clinical Practice Guidelines

scientific article published on 01 September 2011

Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself.

artículo científico publicado en 2006

Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer

artículo científico publicado en 2009

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer

artículo científico publicado en 2009

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

artículo científico publicado en 2016

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner

artículo científico publicado en 2006

Breast cancer

scientific article published on 23 September 2019

Breast cancer gene expression profiling: clinical trial and practice implications

artículo científico publicado en 2005

Breast cancer in 2014: A call back to reality!

artículo científico

Breast cancer in pregnancy: recommendations of an international consensus meeting

scientific article published on December 2010

Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative.

artículo científico publicado en 2011

Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe!

scientific article published on 19 July 2017

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

artículo científico publicado en 2006

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

artículo científico publicado en 2021

Bringing molecular prognosis and prediction to the clinic.

artículo científico publicado en 2005

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

artículo científico publicado en 2020

Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

artículo científico publicado en 2011

Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma

scientific article published on 01 December 2001

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

artículo científico publicado en 2016

Challenges in breast cancer clinical trial design in the postgenomic era.

artículo científico publicado en 2004

Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference

artículo científico

Chemoprevention for breast cancer

artículo científico publicado en 2012

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

artículo científico publicado en 2008

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer

artículo científico publicado en 2012

Clinical application of the 70-gene profile: the MINDACT trial

artículo científico publicado en 2008

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

artículo científico publicado en 2010

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

artículo científico publicado en 2010

Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer

scholarly article

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

artículo científico publicado en 2002

Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

article

Comparison of prognostic gene expression signatures for breast cancer

artículo científico publicado en 2008

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

artículo científico publicado en 2020

Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.

artículo científico publicado en 2002

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

artículo científico publicado en 2005

Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer

article

Corrigendum: Management of locally advanced breast cancer--perspectives and future directions

artículo científico publicado en 2015

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

artículo científico publicado en 2020

Current models, challenges and best practices for work conducted between European academic cooperative groups and industry

scientific article published on 01 March 2020

Current perspectives of epothilones in breast cancer.

artículo científico publicado en 2008

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

artículo científico publicado en 2009

Digital analysis of distant and cancer-associated mammary adipocytes

artículo científico publicado en 2020

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be t

artículo científico publicado en 2016

Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study

artículo científico publicado en 2001

E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

artículo científico publicado en 2016

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

scientific article published on 01 May 2020

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

artículo científico publicado en 2014

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

artículo científico publicado en 2017

Editorial: Overdoing in breast cancer: The risks of over-screening, over-diagnosing and over-treating the disease

scientific article published on 28 October 2016

Enhancing global access to cancer medicines

artículo científico publicado en 2020

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

artículo científico publicado en 2014

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

artículo científico publicado en 2011

European Breast Cancer Conference manifesto on breast centres/units

artículo científico publicado en 2017

European perspective for effective cancer drug development

artículo científico publicado en 2014

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing

artículo científico

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

artículo científico publicado en 2001

Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys

artículo científico publicado en 2016

Facts and controversies in the use of trastuzumab in the adjuvant setting

artículo científico publicado en 2008

First international consensus guidelines for breast cancer in young women (BCY1).

artículo científico

First-Line Treatment of Metastatic Breast Cancer

From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care.

artículo científico publicado en 2016

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

artículo científico publicado en 2006

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

artículo científico publicado en 2013

Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015).

artículo científico publicado en 2018

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

artículo científico publicado en 2018

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

artículo científico publicado en 2015

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice

artículo científico publicado en 2002

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

artículo científico publicado en 2011

Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials ⬇️

artículo científico publicado en 2016

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial

scientific article published on April 2014

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

artículo científico publicado en 2009

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

artículo científico publicado en 2010

Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

scientific article published on 01 April 2008

Individualization of therapy using Mammaprint: from development to the MINDACT Trial

artículo científico publicado en 2007

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

artículo científico publicado en 2013

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

artículo científico publicado en 2010

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

artículo científico publicado en 2009

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.

artículo científico publicado en 2003

Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer

artículo científico publicado en 2002

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2010

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2012

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2011

Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

artículo científico publicado en 2009

Male breast cancer: a disease distinct from female breast cancer

scientific article published on 28 September 2018

Mammographic screening detects low-risk tumor biology breast cancers

artículo científico publicado en 2014

Management of locally advanced breast cancer-perspectives and future directions

artículo científico publicado en 2015

Metastatic breast cancer patients: the forgotten heroes!

artículo científico publicado en 2009

Microarray technology and its effect on breast cancer (re)classification and prediction of outcome ⬇️

artículo científico publicado el 9 de octubre de 2003

Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer

artículo científico publicado en 2019

Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing

scientific article published on 01 February 2006

Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization.

artículo científico publicado en 2016

Molecular targeted therapies in breast cancer: where are we now?

artículo científico publicado en 2007

Multidisciplinary meeting on male breast cancer: summary and research recommendations

artículo científico publicado en 2010

Multifactorial approach to predicting resistance to anthracyclines

artículo científico publicado en 2011

Neoadjuvant endocrine therapy: for whom, for how long?

artículo científico publicado en 2012

Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.

artículo científico publicado en 2012

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours

artículo científico publicado en 2003

New tools for assessing breast cancer recurrence.

artículo científico publicado en 2008

News in the medical treatment of breast cancer

artículo científico publicado en 2003

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

artículo científico publicado en 2003

OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy

article

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment

artículo científico publicado en 2013

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.

artículo científico publicado en 2015

PARP inhibitors coming of age

artículo científico publicado en 2020

Pembrolizumab for Early Triple-Negative Breast Cancer

artículo científico publicado en 2020

Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials

scientific article published on 25 March 2013

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

artículo científico publicado en 2018

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

artículo científico publicado en 2013

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2010

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

artículo científico publicado en 2005

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

artículo científico

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

scientific article published on 01 June 2005

Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer

artículo científico publicado en 2004

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also

artículo científico publicado en 2015

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

artículo científico publicado en 2002

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

artículo científico publicado en 2015

Prevalence of silent breast cancer in autopsy specimens, as studied by the disease being held by image-guided biopsies: The pilot study and literature review

artículo científico

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2011

Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference

scientific article published on 09 January 2018

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

artículo científico publicado en 2005

Putting words into practice

artículo científico publicado en 2019

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

artículo científico publicado en 2004

Recent advances in adjuvant systemic therapy for early-stage breast cancer.

artículo científico publicado en 2008

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer

scientific article published on 12 December 2019

Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al.

artículo científico publicado en 2013

Reply to letter from Suguatti et al

artículo científico publicado en 2017

Reply to the letter to the editor ‘Insertion of central venous catheters (CVCs): any changes in the past ten years’ by Biffi et al

scientific article published on 31 March 2016

Resistance to trastuzumab: a necessary evil or a temporary challenge?

artículo científico publicado en 2002

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

artículo científico publicado en 2010

Review on the clinical use of eribulin mesylate for the treatment of breast cancer.

artículo científico publicado en 2016

Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature

article

Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools

artículo científico publicado en 2007

SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC)

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

artículo científico publicado en 2017

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

artículo científico publicado en 2002

Second international consensus guidelines for breast cancer in young women (BCY2).

artículo científico publicado en 2016

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast c

artículo científico publicado en 2003

Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice? ⬇️

artículo científico publicado el 1 de octubre de 2003

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status

artículo científico publicado en 2016

Small breast cancers: when and how to treat

artículo científico publicado en 2014

Squamous cell carcinoma of the breast

artículo científico publicado en 2000

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial

artículo científico publicado en 2020

Stemming resistance to HER-2 targeted therapy

artículo científico publicado en 2009

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

artículo científico publicado en 2007

Sunitinib in breast cancer: friend or foe.

artículo científico publicado en 2009

Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

artículo científico

Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?

artículo científico publicado en 2016

Tamoxifen therapy for patients with breast cancer

artículo científico publicado en 2013

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

article

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

artículo científico publicado en 2011

The MINDACT trial: the first prospective clinical validation of a genomic tool

artículo científico publicado en 2007

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"?

artículo científico publicado en 2018

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review

artículo científico publicado en 2015

The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and [...]

artículo científico publicado en 2002

The need for post-mastectomy radiotherapy in patients with IBC.

artículo científico publicado en 2015

The new generation of breast cancer clinical trials: the right drug for the right target

artículo científico publicado en 2008

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

artículo científico publicado en 2007

The pipeline of new anticancer agents for breast cancer treatment in 2003 ⬇️

artículo científico publicado el 1 de octubre de 2003

The requirements of a specialist breast centre

scientific article published on 26 February 2020

The voice of youth.

artículo científico publicado en 2006

Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box

artículo científico publicado en 2020

Time for more optimism in metastatic breast cancer?

artículo científico publicado en 2013

Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

artículo científico publicado en 2019

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design

artículo científico

Use and abuse of taxanes in the management of metastatic breast cancer.

artículo científico publicado en 2003

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

artículo científico publicado en 2006

Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

artículo científico publicado en 2020

[Chronic diarrhea as late complication of partial gastrectomy]

scientific article published on 01 September 2000

[Regional Cancer Registry and clinical research in Portugal: challenges and opportunities].

artículo científico publicado en 2014

[Towards an individualization of systemic treatment of breast tumors]

artículo científico publicado en 2006

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

article

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda